144 related articles for article (PubMed ID: 22088139)
1. Chemical interactions between an active pharmaceutical ingredient and its counterion in a tromethamine salt under forced degradation conditions.
Loeser E; Sutton P; Skorodinsky A; Lin M; Yowell G
Drug Dev Ind Pharm; 2012 Mar; 38(3):357-64. PubMed ID: 22088139
[TBL] [Abstract][Full Text] [Related]
2. Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances.
Bao Y; Mo X; Xu X; He Y; Xu X; An H
J Pharm Biomed Anal; 2008 Nov; 48(3):664-71. PubMed ID: 18678459
[TBL] [Abstract][Full Text] [Related]
3. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.
David SE; Timmins P; Conway BR
Drug Dev Ind Pharm; 2012 Jan; 38(1):93-103. PubMed ID: 22118222
[TBL] [Abstract][Full Text] [Related]
4. A HILIC method for the analysis of tromethamine as the counter ion in an investigational pharmaceutical salt.
Guo Y; Huang A
J Pharm Biomed Anal; 2003 Apr; 31(6):1191-201. PubMed ID: 12667935
[TBL] [Abstract][Full Text] [Related]
5. Identification of oxidative degradates of the TRIS salt of a 5,6,7,8-tetrahydro-1,8-naphthyridine derivative by LC/MS/MS and NMR spectroscopy--interactions between the active pharmaceutical ingredient and its counterion.
Wu Y; Hwang TL; Algayer K; Xu W; Wang H; Procopio A; DeBusi L; Yang CY; Matuszewska B
J Pharm Biomed Anal; 2003 Dec; 33(5):999-1015. PubMed ID: 14656591
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Insight into Chemical Stability of Important Antidiabetic Drug Vildagliptin Using Chromatography (LC-UV and UHPLC-DAD-MS) and Spectroscopy (Mid-IR and NIR with PCA).
Gumieniczek A; Berecka-Rycerz A; Fornal E; Żyżyńska-Granica B; Granica S
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577104
[TBL] [Abstract][Full Text] [Related]
7. An investigation into the influence of counterion on the properties of some amorphous organic salts.
Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
[TBL] [Abstract][Full Text] [Related]
8. Solid state compatibility studies with tablet excipients using non thermal methods.
Liltorp K; Larsen TG; Willumsen B; Holm R
J Pharm Biomed Anal; 2011 Jun; 55(3):424-8. PubMed ID: 21411259
[TBL] [Abstract][Full Text] [Related]
9. pH control of nucleophilic/electrophilic oxidation.
Freed AL; Strohmeyer HE; Mahjour M; Sadineni V; Reid DL; Kingsmill CA
Int J Pharm; 2008 Jun; 357(1-2):180-8. PubMed ID: 18400425
[TBL] [Abstract][Full Text] [Related]
10. Chemometrics Approaches in Forced Degradation Studies of Pharmaceutical Drugs.
Roberto de Alvarenga Junior B; Lajarim Carneiro R
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652589
[TBL] [Abstract][Full Text] [Related]
11. Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations.
Stanisz B; Regulska K; Kania J; Garbacki P
Drug Dev Ind Pharm; 2013 Jan; 39(1):51-61. PubMed ID: 22348774
[TBL] [Abstract][Full Text] [Related]
12. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility.
Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA
Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882
[TBL] [Abstract][Full Text] [Related]
13. The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations.
Wu Y
Biomed Chromatogr; 2000 Oct; 14(6):384-96. PubMed ID: 11002276
[TBL] [Abstract][Full Text] [Related]
14. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
Cooper VB; Pearce GE; Petts CR
J Pharm Pharmacol; 2003 Sep; 55(9):1323-9. PubMed ID: 14604477
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a stable molecular complex of an API with HCl: a long journey to a conventional salt.
Peresypkin A; Variankaval N; Ferlita R; Wenslow R; Smitrovich J; Thompson K; Murry J; Crocker L; Mathre D; Wang J; Harmon P; Ellison M; Song S; Makarov A; Helmy R
J Pharm Sci; 2008 Sep; 97(9):3721-6. PubMed ID: 18240276
[TBL] [Abstract][Full Text] [Related]
16. A case study where pharmaceutical salts were used to address the issue of low in vivo exposure.
Sigfridsson K; Ulvinge ML; Svensson L; Granath AK
Drug Dev Ind Pharm; 2019 Feb; 45(2):202-211. PubMed ID: 30256689
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of drug physical form during granulation, tabletting and storage.
Williams AC; Cooper VB; Thomas L; Griffith LJ; Petts CR; Booth SW
Int J Pharm; 2004 May; 275(1-2):29-39. PubMed ID: 15081136
[TBL] [Abstract][Full Text] [Related]
18. Understanding pharmaceutical polymorphic transformations I: influence of process variables and storage conditions.
Sood J; Sapra B; Bhandari S; Jindal M; Tiwary AK
Ther Deliv; 2014 Oct; 5(10):1123-42. PubMed ID: 25418270
[TBL] [Abstract][Full Text] [Related]
19. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
[TBL] [Abstract][Full Text] [Related]
20. Quantification of potential impurities by a stability indicating UV-HPLC method in niacinamide active pharmaceutical ingredient.
Thomas S; Bharti A; Tharpa K; Agarwal A
J Pharm Biomed Anal; 2012 Feb; 60():86-90. PubMed ID: 22115882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
